Incyte Corporation (INCY)

77.40
-0.61(-0.78%)
After Hours
77.42
+0.02(+0.03%)
- Real-time Data
  • Volume:
    1,534,480
  • Bid/Ask:
    76.77/78.58
  • Day's Range:
    77.23 - 78.62

INCY Overview

Prev. Close
78.01
Day's Range
77.23-78.62
Revenue
2.7B
Open
78.51
52 wk Range
75.52-102.59
EPS
2.17
Volume
1,534,480
Market Cap
17.02B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,248,238
P/E Ratio
35.91
Beta
0.77
1-Year Change
-21.05%
Shares Outstanding
219,923,477
Next Earnings Date
Aug 03, 2021
What is your sentiment on Incyte Corporation?
or
Market is currently closed. Voting is open during market hours.

Incyte Corporation News

Incyte Corporation Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellStrong SellStrong SellSell
Technical IndicatorsNeutralStrong SellSellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Incyte Corporation Company Profile

Incyte Corporation Company Profile

Employees
1773

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Read More
  • Google play Khmer🌟
    0
    • Why is this guy down?
      1
      • What is going on this stock? It has been dipping with no limit?!
        1
        • beat Earnings, why down?
          3
          • Turkish biotechnology company produces RTALB diagnostic kit. Its products are in demand in 15 countries. The company has exported more than 2 million kits in the past month.
            2
            • This is why the stock lost 44% for the year? Who said $175?
              1
              • goes to 50...hmm
                1
                • Papa Putin said so?
                  2
              • This stock is conservatively worth $105. I wouldn't be surprised if its closer to $175 than $100 by the end of the yr.
                2
                • Also, one of the finest stock research letters (Oxford Communique) loved it at $100 and deemed it one of their Ten-Bagger portfolio stocks. The Oxford Club knows what they're talking about too.
                  1
                • Yeah, totally.
                  1
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.